GSK: FDA approves Ojjaara
(CercleFinance.com) - On Friday evening GSK announced that the US FDA had approved Ojjaara for the treatment of myelofibrosis associated with anemia, thereby becoming the first and only drug expressly approved for this indication.
Myelofibrosis, a cancer of the blood that affects around 25,000 people in the US, leads in most cases to anemia, forcing patients to stop their treatment and have blood transfusions.
GSK got its hands on momelotinib, the scientific name of Ojjaara, last year as part of the $1.9bn takeover of Californian biotech Sierra Oncology.
At the time, the British laboratory said it expected the drug to generate sales as early as FY 2023, before generating "significant" growth thereafter.
GSK says that Ojjaara is not currently approved in any other country.
Copyright (c) 2023 CercleFinance.com. All rights reserved.